Alyeska Investment Group
NRIX icon

Alyeska Investment Group’s Nurix Therapeutics NRIX Stock Holding History

Alyeska Investment Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-120,750
Closed -$1.69M – 636
2022
Q1 		$1.69M Buy
120,750
+5,750
+5% +$102K 0.02% 450
2021
Q4 		$3.33M Hold
115,000
– – 0.04% 360
2021
Q3 		$3.44M Buy
+115,000
New +$3.55M 0.04% 401

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Alyeska Investment Group's NRIX Position: Q2 2022 in Review

Alyeska Investment Group sold out of Nurix Therapeutics (NRIX) in Q2 2022, closing a stake of 120,750 shares — an estimated $1.69M sold.

Alyeska Investment Group first reported a position in NRIX in Q3 2021 and held it in 3 quarters. The position peaked at $3.44M in Q3 2021. 106 funds tracked by Wall St. Rank hold NRIX as of Q2 2022.

  • Alyeska Investment Group reported no remaining Nurix Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 120,750 Nurix Therapeutics shares in Q2 2022, an estimated $1.69M.
  • Alyeska Investment Group first reported a position in Nurix Therapeutics in Q3 2021 and held it in 3 quarters.
  • Alyeska Investment Group's Nurix Therapeutics position peaked at $3.44M in Q3 2021.
  • 106 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2022.

Based on Alyeska Investment Group's 13F filing for Q2 2022, filed 15 Aug 2022.